LGT Fund Management Co Ltd. Makes New $2.26 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX

LGT Fund Management Co Ltd. bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 5,063 shares of the pharmaceutical company’s stock, valued at approximately $2,261,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Motiv8 Investments LLC purchased a new position in Vertex Pharmaceuticals in the 4th quarter worth approximately $26,000. Swiss RE Ltd. purchased a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at $28,000. Eagle Bay Advisors LLC acquired a new stake in Vertex Pharmaceuticals during the 4th quarter valued at $29,000. IMG Wealth Management Inc. increased its stake in Vertex Pharmaceuticals by 277.8% during the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock worth $31,000 after buying an additional 50 shares during the period. Finally, Ares Financial Consulting LLC acquired a new position in Vertex Pharmaceuticals in the 4th quarter worth $33,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $485.39 on Monday. The company has a market cap of $123.19 billion, a PE ratio of 28.79, a P/E/G ratio of 2.07 and a beta of 0.29. The business’s 50 day moving average is $457.12 and its two-hundred day moving average is $458.32. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $533.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. The business had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the business earned $4.06 EPS. As a group, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 17.07 EPS for the current fiscal year.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex’s $10 billion acquisition of Crinetics is being seen as a major expansion move that could add future growth drivers beyond its core cystic fibrosis business. Article Title
• Positive Sentiment: Investors continue to highlight Vertex as a strong long-term compounder, with articles pointing to its decade-long stock performance and durable earnings power. Article Title
• Positive Sentiment: Coverage on Vertex as one of the best QQQ stocks emphasized the July 1 FDA expansion for CASGEVY, which strengthened the company’s gene-therapy growth story. Article Title
• Positive Sentiment: Additional biotech commentary has kept Vertex in focus as one of the sector’s more attractive names, reinforcing investor interest in the stock. Article Title
• Neutral Sentiment: Short-interest data was reported at zero shares, which does not provide a meaningful trading signal and is unlikely to move the stock on its own.
• Neutral Sentiment: Several other biotech articles mentioned Vertex only in passing or as part of broader sector coverage, with limited direct impact on VRTX.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 1,500 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total value of $787,485.00. Following the transaction, the executive vice president directly owned 45,321 shares in the company, valued at approximately $23,793,071.79. This trade represents a 3.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joy Liu sold 1,104 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $425.02, for a total transaction of $469,222.08. Following the completion of the transaction, the executive vice president directly owned 20,729 shares of the company’s stock, valued at $8,810,239.58. This trade represents a 5.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 18,874 shares of company stock valued at $8,707,966 over the last quarter. Insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Canaccord Genuity Group lowered their target price on Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating for the company in a research note on Tuesday, May 5th. Barclays raised their price objective on Vertex Pharmaceuticals from $607.00 to $615.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Weiss Ratings downgraded Vertex Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 30th. Sanford C. Bernstein reduced their target price on Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. Finally, Maxim Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $575.00 price target for the company in a research report on Wednesday, March 18th. Twenty-one analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $557.09.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.